Hépatites fulminantes sous tolcapone = Fulminant hepatitis under tolcaponeLa Revue Prescrire. 1998, Vol 18, Num 189, issn 0247-7750, p. 767Article

Effets indésirables hépatiques graves sous tolcapone survenus 17 mois après le début du traitement = Serious tolpcapone-induced hepatitis 17 months after commencing treatmentKORRI, H; AWADA, A.Revue neurologique (Paris). 2005, Vol 161, Num 11, pp 1113-1115, issn 0035-3787, 3 p.Article

Improvement of Prepulse Inhibition and Executive Function by the COMT Inhibitor Tolcapone Depends on COMT Val 158Met Polymorphism : Catechol-O-Methyl Transferase (COMT), Recent FindingsGIAKOUMAKI, Stella G; ROUSSOS, Panos; BITSIOS, Panos et al.Neuropsychopharmacology (New York, NY). 2008, Vol 33, Num 13, pp 3058-3068, issn 0893-133X, 11 p.Article

Tolcapone: A review of its use in the management of Parkinson's DiseaseKEATING, Gillian M; LYSENG-WILLIAMSON, Katherine A.CNS drugs. 2005, Vol 19, Num 2, pp 165-184, issn 1172-7047, 20 p.Article

Switch-over from tolcapone to entacapone in severe Parkinson's disease patientsONOFRJ, M; THOMAS, A; LACONO, D et al.European neurology. 2001, Vol 46, Num 1, pp 11-16, issn 0014-3022Article

Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcaponeJORGA, K; BANKEN, L; FOTTELER, B et al.Clinical pharmacology and therapeutics. 2000, Vol 67, Num 6, pp 610-620, issn 0009-9236Article

Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patientsMovement disorders. 1999, Vol 14, Num 1, pp 38-44, issn 0885-3185Article

Tolcapone : A novel approach to Parkinson's diseaseMICEK, S. T; ERNST, M. E.American journal of health-system pharmacy. 1999, Vol 56, Num 21, pp 2195-2205, issn 1079-2082Article

Prospects for new drug treatment in idiopathic parkinsonismSAMII, A; LETWIN, S. R; CALNE, D. B et al.Drug discovery today. 1998, Vol 3, Num 3, pp 131-140, issn 1359-6446Article

Randomized, placebo-controlled study of Tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopaADLER, C. H; SINGER, C; O'BRIEN, C et al.Archives of neurology (Chicago). 1998, Vol 55, Num 8, pp 1089-1095, issn 0003-9942Article

Tolcapone and fulminant hepatitisASSAL, F; SPAHR, L; HADENGUE, A et al.Lancet (British edition). 1998, Vol 352, Num 9132, issn 0140-6736, p. 958Article

Tolcapone: COMT inhibition for the treatment of Parkinson's diseaseFAHN, Stanley.Neurology. 1998, Vol 50, Num 5, issn 0028-3878, 62 p., SUP5Serial Issue

Extending levodopa action : COMT inhibitionMARTINEZ-MARTIN, P; O'BRIEN, C. F.Neurology. 1998, Vol 50, Num 6, pp S27-S32, issn 0028-3878, SUP6Conference Paper

New pharmacotherapy for Parkinson's diseaseGOTTWALD, M. D; BAINBRIDGE, J. L; DOWLING, G. A et al.The Annals of pharmacotherapy. 1997, Vol 31, Num 10, pp 1205-1217, issn 1060-0280Article

Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male ratsKHROMOVA, I; VORONINA, T; KRAINEVA, V. A et al.Behavioural brain research. 1997, Vol 86, Num 1, pp 49-57, issn 0166-4328Article

COMT Val¹⁵⁸Met Genotype Determines the Direction of Cognitive Effects Produced by Catechol-O-Methyltransferase InhibitionFARRELL, Sarah M; TUNBRIDGE, Elizabeth M; BRAEUTIGAM, Sven et al.Biological psychiatry (1969). 2012, Vol 71, Num 6, pp 538-544, issn 0006-3223, 7 p.Article

Jeu pathologique sous tolcapone = Tolcapone and pathological gamblingLa Revue Prescrire. 2010, Vol 30, Num 325, issn 0247-7750, p. 830Conference Paper

Management of L-Dopa related hyperhomocysteinemia : catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a reviewZOCCOLELLA, Stefano; LLICETO, Giovanni; DEMARI, Michele et al.Clinical chemistry and laboratory medicine. 2007, Vol 45, Num 12, pp 1607-1613, issn 1434-6621, 7 p.Conference Paper

Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the ratHAASIO, K; SOPANEN, L; VAALAVIRTA, L et al.Journal of neural transmission. 2001, Vol 108, Num 1, pp 79-91, issn 0300-9564Article

Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PDSUCHOWERSKY, Oksana; BAILEY, Peter; POURCHER, E et al.Clinical neuropharmacology. 2001, Vol 24, Num 4, pp 214-220, issn 0362-5664Article

Gait analysis in advanced Parkinson's disease : Effect of levodopa and tolcaponeSHAN, Din-E; LEE, Shwn-Jen; CHAO, Ling-Yi et al.Canadian journal of neurological sciences. 2001, Vol 28, Num 1, pp 70-75, issn 0317-1671Article

COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients on levodopa/carbidopa (Sinemet®)JORGA, K. M; NICHOLL, D. J.British journal of clinical pharmacology. 1999, Vol 48, Num 3, pp 449-452, issn 0306-5251Article

Determination of the catechol-O-methyltransferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detectionHEIZMANN, P; SCHMITT, M; LEUBE, J et al.Journal of chromatography. B, Biomedical sciences and applications. 1999, Vol 730, Num 2, pp 153-160, issn 1387-2273Article

COMT inhibition in the treatment of Parkinson's diseaseRUOTTINEN, H. M; RINNE, U. K.Journal of neurology. Supplement. 1998, Vol 245, Num 3, pp P25-P34, issn 0939-1517Conference Paper

Tolcapone in stable Parkinson's disease : Efficacy and safety of long-term treatmentWATERS, C. H; KURTH, M; BAILEY, P et al.Neurology. 1998, Vol 50, Num 5, pp S39-S45, issn 0028-3878, SUP5Article